Supervised resistance exercise for women with ovarian cancer who have completed first-line treatment: a pragmatic study

被引:8
作者
Schofield, Christelle [1 ,5 ]
Newton, Robert U. [1 ,5 ]
Taaffe, Dennis R. [1 ,5 ]
Galvao, Daniel A. [1 ,5 ]
Cohen, Paul A. [2 ,3 ,5 ]
Meniawy, Tarek M. [2 ,3 ,4 ,5 ]
Peddle-McIntyre, Carolyn J. [1 ,5 ]
机构
[1] Edith Cowan Univ, Exercise Med Res Inst, Joondalup, WA, Australia
[2] Univ Western Australia, Sch Med, Crawley, WA, Australia
[3] St John God Hosp, Subiaco, WA, Australia
[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[5] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA, Australia
关键词
Ovarian cancer; Resistance exercise; Muscle mass; Muscle strength; Physical function; FEMALE PELVIC FLOOR; QUALITY-OF-LIFE; OLDER-ADULTS; ACTIVITY BEHAVIORS; PHYSICAL-ACTIVITY; CONTROLLED-TRIAL; CHEMOTHERAPY; SURVIVORS; MYOSTEATOSIS; SARCOPENIA;
D O I
10.1007/s00520-023-07754-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectivesIn ovarian cancer (OC), suboptimal muscle morphology (i.e., low muscle mass and density) is associated with poor clinical outcomes, yet little is known about the effect of interventions aimed at improving these measures. We investigated the effect of resistance exercise after first-line treatment on muscle mass and density, muscle strength and physical function, health-related quality of life (QoL), and pelvic-floor function in advanced-stage OC survivors.MethodsFifteen OC survivors participated in supervised resistance exercise twice weekly for 12 weeks (in-clinic or by telehealth). Assessments included muscle mass and density (dual-energy X-ray absorptiometry, peripheral quantitative computed tomography), muscle strength (1-repetition maximum [1RM] chest press, 5RM leg press, handgrip strength), physical function (400-m walk, timed up-and-go [TUG]), QoL (QLQ-C30 questionnaire), and self-reported pelvic floor function (Australian Pelvic Floor Questionnaire).ResultsThe median age was 64 (range 33-72) years, 10 women underwent neoadjuvant chemotherapy and five underwent adjuvant chemotherapy. All participants completed the intervention (median attendance = 92%; range 79-100%). Post-intervention improvements were observed for whole-body lean mass (1.0 +/- 1.4 kg, p = 0.015), appendicular lean mass (0.6 +/- 0.9 kg, p = 0.013), muscle density (p = 0.011), upper and lower body strength (p <= 0.001), 400-m walk (p = 0.001), TUG (p = 0.005), and social and cognitive QoL domains (p = 0.002 and 0.007), with no change to pelvic floor symptoms (p > 0.05).ConclusionIn this study, supervised resistance exercise effectively improved muscle mass and density, muscle strength, and physical functioning without deleterious effects on the pelvic floor. Considering the prognostic value of these outcomes, larger studies are needed to confirm the benefits of resistance exercise in OC supportive care.
引用
收藏
页数:12
相关论文
共 50 条
[42]   Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer [J].
Vergote, I ;
du Bois, A. ;
Floquet, A. ;
Rau, J. ;
Kim, J-W ;
del Campo, J. M. ;
Friedlander, M. ;
Pignata, S. ;
Fujiwara, K. ;
Colombo, N. ;
Mirza, M. R. ;
Monk, B. J. ;
Tsibulak, I ;
Calvert, P. M. ;
Herzog, T. J. ;
Hanker, L. C. ;
Meunier, J. ;
Lee, J-Y ;
Bologna, A. ;
Carrasco-Alfonso, M. J. ;
Harter, P. .
GYNECOLOGIC ONCOLOGY, 2019, 155 (02) :186-191
[43]   Effectiveness and safety of nab- paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study [J].
Wang, Liangliang ;
Li, Shuangying ;
Zhu, Da ;
Qin, Yu ;
Wang, Xiaoli ;
Hong, Zhenya ;
Han, Zhiqiang .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (04)
[44]   Secondary cytoreductive surgery for ovarian cancer recurrence and first-line maintenance therapy: A multicenter retrospective study [J].
Uccella, Stefano ;
Puppo, Andrea ;
Garzon, Simone ;
Palladino, Simona ;
Zorzato, Pier Carlo ;
Maggiore, Umberto Leone Roberti ;
Zavallone, Laura ;
Calandra, Valerio ;
Galli, Liliana ;
Franchi, Massimo ;
Raspagliesi, Francesco .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2025, 306 :160-167
[45]   Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer [J].
Friedlander, M. ;
Buck, M. ;
Wyld, D. ;
Findlay, M. ;
Fitzharris, B. ;
De Souza, P. ;
Davies, T. ;
Kalimi, G. ;
Allan, S. ;
Perez, D. ;
Harnett, P. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) :350-358
[46]   Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: Feasibility and toxicity [J].
Meden, H ;
Wittkop, Y ;
Kuhn, W .
ANTICANCER RESEARCH, 1997, 17 (3C) :2221-2223
[47]   Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer [J].
Goh, Jeffrey C. H. ;
Gourley, Charlie ;
Tan, David S. P. ;
Nogueira-Rodrigues, Angelica ;
Elghazaly, Hesham ;
Pierre, Marc Edy ;
Giornelli, Gonzalo ;
Kim, Byoung-Gie ;
Morales-Vasquez, Flavia ;
Tyulyandina, Alexandra .
GYNECOLOGIC ONCOLOGY REPORTS, 2022, 42
[48]   Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients [J].
Sehouli, Jalid ;
Mustea, Alexander ;
Oskay-Ozcelik, Guelten ;
Keller, Maren ;
Richter, Rolf ;
Tome, Oliver ;
Woopen, Hannah ;
Sommer-Joos, Ann-Katrin ;
Grabowski, Jacek P. P. ;
Armbrust, Robert ;
Wimberger, Pauline .
CANCERS, 2021, 13 (19)
[49]   A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer [J].
Li, Siyuan ;
Zhang, Yanqin ;
Yang, Rong ;
Yang, Qingfan ;
Han, Shuangyan ;
Li, Dan ;
Zhang, Zhenhua ;
Wen, Qinglian .
ANTI-CANCER DRUGS, 2025, 36 (05) :394-400
[50]   Physical and functional well-being and symptoms of ovarian cancer in women undergoing first-line of chemotherapy: a one-year follow-up [J].
Amanda Canato Ferracini ;
Gabriela Pereira ;
Cinthia Madeira de Souza ;
Thiago Fortes Cabello dos Santos ;
Luís Otávio Sarian ;
Sophie Derchain ;
Priscila Gava Mazzola .
Supportive Care in Cancer, 2021, 29 :7421-7430